Open Access

Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model

Arthritis Research & Therapy201517:142

https://doi.org/10.1186/s13075-015-0653-y

Received: 24 October 2014

Accepted: 12 May 2015

Published: 29 May 2015

Abstract

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of the joints and bones. Omega-3 (ω3) fatty acid supplementation has been associated with a decreased production of inflammatory cytokines and eicosanoids involved in RA pathogenesis. The aim of this study was to determine the therapeutic potential of ω3 monoglyceride (MAG-ω3) compounds in an in vivo rat model of RA induced by Complete Freund’s Adjuvant (CFA).

Method

CFA rats were untreated or treated per os with three specific compounds, namely, MAG-docosahexaenoic acid (MAG-DHA), MAG-eicosapentaenoic acid (MAG-EPA) and MAG-docosapentaenoic acid (MAG-DPA). Morphological and histological analyses, as well as pro-inflammatory marker levels were determined following MAG-ω3 treatments.

Results

Morphological and histological analyses revealed that MAG-EPA and MAG-DPA exhibited strong activity in reducing the progression and severity of arthritic disease in CFA rats. Following MAG-EPA and MAG-DPA treatments, plasma levels of the pro-inflammatory cytokines; interleukin 17A (IL-17A), IL-1β, IL-6 and tumor necrosis factor α (TNFα) were markedly lower when compared to CFA-untreated rats. Results also revealed a decreased activation of p38 mitogen-activated protein kinases (p38 MAPK) and nuclear factor-kappa B (NFκB) pathways correlated with a reduced expression of TNFα, cyclooxygenase-2 (COX-2), matrix metalloproteinase-2 (MMP-2) and MMP-9 in paw homogenates derived from MAG-EPA and MAG-DPA-treated rats. Of interest, the combined treatment of MAG-EPA and vitamin E displayed an antagonistic effect on anti-inflammatory properties of MAG-EPA in CFA rats.

Conclusion

Altogether, the present data suggest that MAG-EPA, without vitamin E, represents a new potential therapeutic strategy for resolving inflammation in arthritis.

Introduction

The severity and disease progression of rheumatoid arthritis (RA) are governed by multiple factors including immune, genetic and environmental factors [1]. Joint lesions show infiltration of several immune cells including activated T lymphocytes, macrophages and antibody-secreting B lymphocytes into the synovium concomitant with a proliferation of synoviocyte cells [2, 3]. These latter cells together with new blood vessels form a tissue termed pannus, which leads to progressive destruction of cartilage and bone [2]. This phenomenon is most likely due to cytokine and eicosanoid-mediated induction of destructive enzymes such as matrix metalloproteinases (MMPs) [4]. Synovial fluid from patients with RA contains high levels of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, IL-8, IL-17A and granulocyte/macrophage colony stimulating factor (GMCFS) [5, 6]. Furthermore, both local and systemic levels of each cytokine are linked to disease severity [79]. Immune cells involved in RA usually contain a high proportion of the n-6 arachidonic acid (AA) and low proportions of other 20-carbon polyunsaturated fatty acids (PUFAs), with AA considered to be the major substrate for synthesis of eicosanoids [3]. Eicosanoids produced by both the cyclooxygenase (COX) and lipoxygenase (LOX) pathways are found in the synovial fluid of patients with active RA [10]. For example, expression of COX-2 is increased in the synovium of patients with RA and in joint tissues in rat models of arthritis [10, 11]. Protaglandin E2 (PGE2) and leukotriene B4 (LTB4), two eicosanoids respectively produced by COX and LOX, display a number of pro-inflammatory effects (including increasing vascular permeability), enhance local blood flow, are potent chemotactic agents for leukocytes, induce the release of lysosomal enzymes and enhance the release of reactive oxygen species and cytokines such as TNF-α, IL-1β and IL-6 [4, 10]. They also promote the production of destructive MMPs and stimulate bone resorption [2].

Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently used to decrease pain and inflammation in RA patients [1, 12]. These agents exert their analgesic effects by inhibiting COX. Treatment of RA with NSAIDs, while improving symptoms, may lead to side effects such as gastrointestinal (GI) toxicity, osteoporosis, diabetes mellitus, weight gain, increased blood pressure, increased risk of heart failure and increased cardiovascular risk [3, 12]. As a result, these adverse effects have led to the restriction of NSAID use for the treatment of RA.

The dietary ω-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), originating from fish oils, are also considered to reduce pain and inflammation in RA via the following mechanisms: ω-3 PUFAs competitively inhibit the production of PGE2 and LTB4, which in turn inhibit the activation of NFκB, and thus the release of inflammatory cytokines such as IL-1β and TNFα [13]. Moreover, ω-3 PUFA-derived mediators, including E-series resolvins (Rvs) such as RvE1 from EPA as well as D-series Rvs and protectin D1 from DHA, exert potent anti-inflammatory, inflammation resolving and immunomodulatory actions both in vitro and in vivo [14]. The ratio of ω6/ω3 PUFAs is important in RA pathogenesis with each of these acids differing in their efficacy. For example, EPA > DHA is effective against inflammation-induced arthritic markers in animal studies [15]. Studies using fish oil in patients with RA report decreased IL-1 production by monocytes [16] and decreased circulating concentrations of IL-1β, TNFα and soluble receptor activator of NFκB ligand [17, 18]. Moreover, clinical trials with ω3 PUFA supplementation have reported an improvement in the number of tender joints on physical examination, the Ritchie articular index, morning stiffness and decreased NSAID requirements [3, 1925]. A meta-analysis of randomized controlled trials confirmed that ω-3 PUFA supplementation improves clinical symptoms of RA [26]. Moreover, a recent clinical trial demonstrated that fish oil used as adjunctive therapy in the context of modern treat-to-target drug treatment for recent onset RA both increased rates of remission and decreased drug use [27]. However, the conclusions of several clinical studies have shown consistent evidence for a modest clinical efficacy of marine ω3 PUFAs in RA.

In light of the above, EPA, DHA and docosapentaenoic acid (DPA) sn1-monoacylglycerides, namely eicosapentaenoic acid monoglyceride (MAG-EPA), docosahexaenoic acid monoglyceride (MAG-DHA) and docosapentaenoic acid monoglyceride (MAG-DPA), were synthesized in order to: 1) evaluate their effects on arthritic disease severity in a complete Freund’s adjuvant (CFA)-induced rat model, and 2) to monitor inflammatory arthritis activity using biochemical and histological analyses. Indeed, MAG-ω3 compounds are well-absorbed by the GI tract, are non-toxic, and their metabolites are found in blood circulation and tissues [2831]. Specifically, we assessed the effects of treatment with MAG-ω3 compounds on morphological, clinical and histological features of arthritis disease. Moreover, the level of inflammatory markers (IL-17A, IL-1β, IL-6, TNFα, COX-2), the activation of p38 mitogen-activated protein kinase (MAPK) and NFκB pathways, as well as the levels of MMP2 and MMP-9 were determined following MAG-ω3 treatments. Results indicated that MAG-EPA and MAG-DPA exert more potent anti-inflammatory and pro-resolving effects than MAG-DHA in a CFA model of arthritis, a finding consistent with the inhibition of NFκB and p38MAPK pathways.

Materials and methods

Synthesis of ω3 PUFA monoacylglycerides

MAG-DHA, MAG-EPA and MAG-DPA were synthesized as previously described [28, 29, 32].

Animal model of arthritis

CFA was used to initiate induction of arthritis. Adult (10 weeks) female Lewis rats weighing 180 to 200 g were obtained from Charles River Laboratories (Montreal, QC, Canada). Rats were housed in our animal facilities in a 12:12-h light-dark cycle, at 22 ± 2 °C ambient temperature, and maintained on normal rodent chow and tap water ad libitum. Rats were acclimated 7 days before starting the experiments. All studies involving animals were approved by the institutional animal care committee of the Université du Québec à Rimouski (Protocol: # CPA-53-13-120). The rats were injected intradermally with 0.2 ml of CFA (Chondrex, Inc. Redmond, WA, USA) at the base of the tail. To increase the severity of arthritis, a booster injection with 0.1 ml of CFA was administered in the same manner on day 5. Measurements were obtained from both the inflamed and non-inflamed hind paws. The hind paw thickness (mm) was measured using a digital caliper. The severity of arthritis in the rats was assessed daily and scoring was attributed semiquantitatively (0: normal, with no macroscopic signs of arthritis; 1: mild, swelling and redness of one joint; 2: moderate, redness and swelling in two joints; 3: redness and swelling in more than two joints; 4: severe arthritis in multiple joints including the entire paw). Rats were randomly assigned into five groups: 1) control; 2) CFA; 3) CFA+ MAG-EPA-treated 4) CFA + MAG-DPA-treated, and 5) CFA + MAG-DHA-treated. MAG-ω3 compounds (318 mg/kg) were given orally directly to the back of the mouth with a pipette tip. MAG-ω3 treatments were administrated daily. The oral dose of 318 mg/kg was chosen according to Health Canada Draft Guidelines to obtain a human equivalent dose of 3.0 g/day (60 % of the maximum daily dose allowed by Health Canada) [33].

Oral administration of MAG-ω3 compounds were initiated 15 days after the initial CFA injection and continued until study termination (day 22). Macroscopic signs of severe arthritis at 20 days included swelling, redness, deformity and ankyloses in the hind paw and ankle joints. At the end of the experiment, all five groups of rats were euthanized by a lethal dose of pentobarbital and blood and tissue samples were collected for further analyses (Scheme 1).
Scheme 1

Experimental design and schedule of treatment in rat model of rheumatoid arthritis

Additional experiments were performed to determine the effect of vitamin E and MAG-EPA treatments in CFA rats. MAG-EPA (318 mg/kg) and vitamin E (53 mg/kg) was given as a single dose orally directly to the back of the mouth with a pipette tip. Combined treatment was administrated daily 15 days following CFA injection after which its effects on hind paw thickness, COX-2 expression levels and pro-inflammatory cytokine profiles were evaluated.

Western blot analysis

Western blots using specific antibodies against the phosphorylated forms of p65 NFκB (P-p65NFκB), p38MAPK (P-p38MAPK), as well as NFκB, p38 MAPK, COX2, TNFα, MMP-2 and MMP-9 and β-actin proteins were performed on hind paw homogenate fractions derived from control and CFA rats, either untreated or treated with MAG-EPA, MAG-DPA or MAG-DHA, as previously described. All antibodies used were obtained from New England BioLabs, Pickering, ON, Canada: 1 μg/ml of the selected specific antibody in TBS-T + 5 % BSA were incubated overnight at 4 °C. Immunostains of the blots were digitized and analyzed with Lab-Image software 2.7.

Histological analysis

Rat tissues were fixed in 10 % buffered formalin and paraffin-embedded after which thin sections (3-μm thick) were stained with hematoxylin-eosin according to standard protocols [29]. Images were acquired with a Hamamatsu ORCA-ER digital camera attached to a Nikon Eclipse TE-2000 inverted microscope (Nikon-Canada, Mississauga, ON, Canada). Images were obtained (objective 20×) from hind paw sections derived from control, CFA, CFA + MAG-DHA-, CFA + MAG-EPA- and CFA + MAG-DPA-treated rats.

ELISA assays

Measurements of key pro-inflammatory cytokines including IL-17A, IL-1β, IL-6 and TNFα were measured by specific ELISA on day 22 in plasma derived from control, CFA, CFA + MAG-DHA-, CFA + MAG-EPA- and CFA + MAG-DPA-treated rats, according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA).

Data analysis and statistics

Results are expressed as means ± standard error of the mean (SEM), with n indicating the number of experiments. Statistical analyses were performed using Sigma Plot 11 and SPSS 14.0 (SPSS-Science, Chicago, IL, USA) using one-way analysis of variance (ANOVA) followed by Dunnett’s post-hoc test. Differences were considered statistically significant when P was <0.05.

Results

Effects of MAG-ω3 on arthritis severity

The anti-inflammatory activity of MAG-DHA, MAG-EPA and MAG-DPA was assessed in a rat CFA model, a widely-used model for human RA. Figure 1a illustrates hind paw diameter measurements from control, CFA, CFA + MAG-DHA-treated, CFA + MAG-EPA-treated and CFA + MAG-DPA-treated rats. Results indicate that 18 days following initial CFA injection, hind paw thickness of CFA-untreated rats was significantly increased (7.32 ± 0.22 mm) when compared to control rats (3.96 ± 0.01 mm, Fig. 1a). MAG-DHA treatment of CFA rats resulted in a transient reduction in hind paw thickness following the first and second treatment day, whereas on day 18 to 22, hind paw thickness measurements increased to reach the same level as that of CFA-untreated rats (Fig. 1a). In contrast, treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats (Fig. 1a). Moreover, data indicated that MAG-EPA displayed a more potent effect on the reduction of hind paw swelling and redness on day 20 to 22 than MAG-DPA treatment (Fig. 1a). The arthritic index represents the grade of arthritis that was used to assess the efficacy of MAG-ω3 compounds. In the CFA group, diseased rats without any treatment showed an increased arthritic index starting on day 10 to a peak on day 18 (Fig. 1b). Compared with CFA group, administration of MAG-DHA did not significantly reduce arthritis score (Fig. 1b). However, MAG-EPA and MAG-DPA were observed to have significant activity in preventing the progression of arthritic disease with the arthritis score significantly lowered in treated CFA rats from day 16 to 22 (Fig. 1b).
Fig. 1

Effects of MAG-ω3 compounds on arthritis severity. a Hind paw thickness (mm) as a function of time (days) was measured in control and in complete Freund’s adjuvant (CFA) rats, either untreated or treated with docosahexaenoic acid monoglyceride (MAG-DHA), eicosapentaenoic acid monoglyceride (MAG-EPA) or docosapentaenoic acid monoglyceride (MAG-DPA) (318 mg/kg). MAG-ω3 compounds were administered at 15 days post-CFA injection onward. Six control and six CFA rats were sacrificed on day 22 at the same time as CFA + MAG-ω3-treated rats for pro-inflammatory marker analyses, whereas six controls and six CFA rats were sacrificed on day 29 to evaluate the progression of arthritis over time. Results represent the mean ± standard error of the mean (n = 6 per group for MAG-ω3-treated animals and n = 12 for control and CFA rats). b Clinical arthritis score as a function of time was determined in untreated and treated CFA rats (n = 12 for untreated and n = 6 for treated conditions). c Macroscopic images of hind paw derived from control, CFA and CFA+MAG-EPA-treated rats. Hematoxylin-eosin staining of hind paw thin sections derived from Control (d): CFA (e) and CFA + MAG-EPA-treated animals (f). Bar = 50 μm

Moreover, as illustrated in Fig. 1c, macroscopic images revealed that MAG-EPA-treatment decreased arthritic symptoms when compared to those observed in the untreated CFA group. Histological analysis of joints in CFA rats demonstrated an extensive proliferation of synovial cells, resulting in pannus formation and infiltration of leukocytes to the sub synovial region, with damage to articular surfaces and discontinuity in the cartilage when compared to histological joint sections obtained from control rats (Fig. 1d-e). However, CFA rats treated with MAG-EPA showed a reduced level of severe arthritic and degenerative changes when compared to the morphological changes observed in the untreated CFA group (Fig. 1f).

Effects of MAG-ω3 on pro-inflammatory cytokine levels

To investigate possible mechanisms by which MAG-ω3 compounds decrease arthritis progression, levels of key pro-inflammatory cytokines including IL-17A, IL-1β, IL-6 and TNFα were measured by specific ELISA on day 22 in plasma derived from control, CFA, CFA + MAG-DHA-, CFA + MAG-EPA- and CFA + MAG-DPA-treated rats. As illustrated in Fig. 2, IL-17A, IL-1β, IL-6 and TNFα levels were significantly higher in the plasma of CFA rats when compared to plasma levels in control animals. In contrast, the levels of these cytokines were significantly lower in the plasma of MAG-EPA- and MAG-DPA-treated animals when compared to untreated CFA rats. Of note, circulating levels of IL-17A, IL-1β, IL-6 and TNFα were less reduced in the presence of MAG-DHA than in MAG-EPA- and MAG-DPA-treated animals.
Fig. 2

Effects of MAG- ω3 treatments on pro-inflammatory cytokine levels. (a) IL-17A, (b) IL-1β, (c) IL-6 and (d) TNFα levels were assessed in plasma of control, complete Freund’s adjuvant (CFA)-treated, CFA + eicosapentaenoic acid monoglyceride (MAG-EPA)-treated, CFA + docosahexaenoic acid monoglyceride (MAG-DHA)-treated and CFA + -docosapentaenoic acid monoglyceride (MAG-DPA)-treated rats using specific ELISA as described in the Methods section (n = 6, *P ≤0.05)

Effect of MAG-ω3 on NFκB pathway activation

P38 MAPK and NFκB pathways are known to contribute to the overexpression of pro-inflammatory cytokines, chemokines, MMPs and signaling enzymes such as COX-2 in the inflamed synovium. In order to determine whether the above anti-inflammatory effects of MAG-ω3 compounds are mediated by these specific pathways, the activation of p38MAPK and NFκB was investigated by western blot in paw homogenates derived from control and CFA rats, either untreated or treated with MAG-EPA, MAG-DPA or MAG-DHA. Western blot analysis revealed that MAG-EPA, MAG-DPA and MAG-DHA treatments all decreased CFA-induced phosphorylation of p38 MAPK to a similar extent compared to untreated CFA animals (Fig. 3a). Western blot and quantitative immunoblot analyses were also performed on hind paw homogenates derived from untreated control and untreated and treated CFA rats using antibodies against total and phosphorylated forms of p65 NFκB. Results revealed that MAG-EPA and MAG-DPA treatments decreased p65 NFκB phosphorylation levels in paw tissues compared to that observed in untreated CFA rats (Fig. 3b), with significant reductions of 81 ± 3.1 % and 76 ± 2.7 %, respectively, following comparative analysis of P-NFκB/NFκB ratios after normalization of identical immunoblot membrane areas (Fig. 5b). However, no significant difference in p65 NFκB phosphorylation levels in CFA + MAG-DHA-treated rats was observed when compared to untreated CFA animals (Fig. 3b).
Fig. 3

Effect of MAG-ω3 on activation of p38 mitogen-activated protein kinase (MAPK) and NFκB pathways. a Western blot and quantitative analysis of hind paw homogenates derived from control complete Freund’s adjuvant (CFA), CFA + eicosapentaenoic acid monoglyceride (MAG-EPA), CFA + docosapentaenoic acid monoglyceride (MAG-DPA) and CFA + docosahexaenoic acid monoglyceride (MAG-DHA)-treated rats using specific antibodies against the phosphorylated form of p38MAPK (P-p38MAPK) and total form of p38MAPK. Staining densities of P-p38MAPK in homogenates are expressed as a function of p38 MAPK signals (n = 6, *P <0.05). b Western blot analysis of the phosphorylated form of p65 NFκB and total form of p65 NFκB in control, untreated CFA and CFA + MAG-ω3- treated rats. Staining densities in paw homogenates are expressed as a function of total p65 NFκB (n = 6, *P <0.05). c Western blot and quantitative analyses of TNFα, cyclooxygenase (COX)-2, and β-actin protein detection derived from control and the four series of CFA-treated rats. Staining densities in homogenates are expressed as a function of β-actin signals. (n = 6, *P <0.05)

We assessed the expression of TNFα and COX-2 in tissue homogenates derived from control as well as untreated and MAG-ω3-treated CFA rats. Results revealed a significant increase in TNFα and COX-2 protein expression in CFA rats when compared to expression levels in control animals. Treatment with MAG-EPA and MAG-DPA, however, reduced TNFα and COX-2 expression levels compared to untreated CFA animals (Fig. 3c, top panel). Following quantitative analysis of identical immunoblot membrane areas normalized as a function of total β-actin staining in corresponding fractions, MAG-EPA and MAG-DPA treatment significantly reduced TNFα and COX-2/β-actin staining density ratios when compared to the ratios quantified in untreated CFA rats (Fig. 3c, lower panels).

Effect of MAG-ω3 treatment on metalloproteinase expression

Further experiments were performed to assess the effect of MAG-DHA, MAG-EPA and MAG-DPA treatments on MMP-2 and MMP-9 expression levels as these proteins have been shown to be involved in the degradation of joint cartilage. Western blot analyses were performed on hind paw and knee cartilage homogenates derived from control, CFA, CFA + MAG-DHA-, CFA + MAG-EPA- and CFA + MAG-DPA-treated rats (Fig. 4). Analysis revealed increased MMP-2 and MMP-9 expression levels in cartilage homogenates derived from CFA rats comparatively to controls. However, a reduced staining of MMP-2 and MMP-9 proteins expression was obtained following treatments with MAG-DHA, MAG-EPA and MAG-DPA compounds in CFA rats (Fig. 4a-c). β-actin staining remained constant from one preparation to the other (Fig. 4a).
Fig. 4

Effects of MAG-ω3 on metalloproteinase expression in paw tissues. a Western blot analysis of hind paw homogenates derived from control, complete Freund’s adjuvant (CFA), CFA + eicosapentaenoic acid monoglyceride (MAG-EPA)-, CFA + docosapentaenoic acid monoglyceride (MAG-DPA)-, and CFA + docosahexaenoic acid monoglyceride (MAG-DHA) -treated rats, using specific antibodies against matrix metalloproteinase (MMP)-2, MMP-9 and β-actin. b Quantitative analysis of MMP-2/β-actin and c MMP-9/β-actin density ratios as a function of experimental conditions (n = 6, *P <0.05)

Effect of vitamin E on MAG-EPA-mediated anti-inflammatory properties

Additional experiments were performed to determine whether vitamin E (commonly used as an antioxidant in omega-3 formulations) exerts synergistic or antagonistic effects on anti-inflammatory properties of MAG-EPA in CFA animals. Combined treatment of vitamin E (53 mg/kg) with MAG-EPA (318 mg/kg) was administrated daily 15 days following CFA injection after which its effects on hind paw thickness, COX-2 expression levels and pro-inflammatory cytokine profiles were investigated. Figure 5a demonstrates that combined treatment of MAG-EPA and vitamin E in CFA rats incurred an increase in hind paw thickness similar to that of CFA-untreated animals. However, treatments with MAG-EPA alone significantly reduced hind paw thickness when compared to untreated CFA rats. The effect of combined MAG-EPA and vitamin E treatment was also assessed on COX2 protein expression by western blot in the different preparations of hind paw homogenates. Figure 5b shows that combined treatment of MAG-EPA and vitamin E inhibited the reduction in COX2 protein expression level observed in CFA + MAG-EPA treated animals. Lastly, the levels of the pro-inflammatory cytokines IL-17A, IL-1β, IL-6 and TNFα were determined in plasma derived from control, CFA- and CFA + MAG-EPA-treated rats in the absence and presence of vitamin E (Fig. 5c). Data demonstrate that combined MAG-EPA and vitamin E treatment also curtailed the effect induced by MAG-EPA on pro-inflammatory cytokine levels in CFA rats (Fig. 5c). Moreover, no significant difference was observed between CFA + MAG-EPA + vitamin E-treated and CFA-untreated rats (Fig. 5c). Taken together, these results indicate that vitamin E displays antagonistic effects on MAG-EPA anti-inflammatory properties in our rat model of RA.
Fig. 5

Effect of vitamin E treatment on eicosapentaenoic acid monoglyceride (MAG-EPA)-induced anti-inflammatory effects in complete Freund’s adjuvant (CFA) rats. a Hind paw thickness (mm) as a function of time (days) was measured in control, CFA, CFA + MAG-EPA-treated rats in the absence and presence of vitamin E (vit E). Results represent the mean ± standard error of the mean (n = 6 per group). b Typical western blots and subsequent quantitative analysis of paw homogenate fractions derived from control, CFA, CFA + MAG-EPA + vitamin E- and CFA+ MAG-EPA-treated rats using specific antibodies against cyclooxygenase (COX)-2 and β-actin. Staining densities in homogenates are expressed as a function of β-actin signals. (n = 6, *P <0.05). c Determination levels of IL-17A, IL-6, IL-1β and TNFα in plasma of control, CFA-treated, CFA + MAG-EPA-treated rats in the absence and presence of vitamin E, (n = 6, *P ≤0.05)

Discussion

The present study shows an anti-inflammatory effect of MAG-ω3 compounds in a rat model of CFA-induced arthritis. The ability of ω3 fatty acids to downregulate several aspects of inflammation suggests that these fatty acids may be important in determining the development and severity of inflammatory diseases and that they may be useful as a component of therapy. Particular interest in the therapeutic potential of ω3 fatty acids in RA was shown quite early on, because of the recognition that these fatty acids target arachidonic acid metabolism known to be involved in this disease. In the present study, we used a CFA model of RA to assess the effects of MAG-EPA, MAG-DPA and MAG-DHA treatment on disease progression and severity. MAG-EPA treatment (human equivalent of 3g/day) during 7 days was found to decrease paw swelling, pro-inflammatory marker levels (IL-17A, IL-6, IL-1β, TNFα, COX-2 and MMPs) as well as disease severity. We propose that MAG-EPA is able to reduce arthritis severity in a CFA rat model.

Anti-inflammatory effects of MAG-ω3 compounds on arthritis severity

Clinical reports have shown that intake of ω3 PUFAs is associated with a reduction in the severity of RA [3, 26]. In the majority of these studies however, a heterogeneous mixture of the two main active ω3 PUFAs was used: EPA and DHA [26, 34]. Many studies have also reported differential effects of EPA, DHA and their metabolites both in a clinical setting and at the laboratory bench.

There are multiple factors that contribute to the differential effects of EPA and DHA, including differences in direct and indirect activation of transcription factors, impact of length, degree of saturation and stability of fatty acids on their efficacy, and differential efficiency for incorporation of the fatty acids into phospholipids [35]. Potency of the metabolites of EPA and DHA are often markedly different to the parent long-chain ω3 PUFA, and divergence in the effectiveness of enzymes to metabolize EPA and DHA can contribute to the observed diversity in cellular response [35]. A preclinical study demonstrated that both EPA and DHA suppressed streptococcal cell wall-induced arthritis in rats, with EPA being the more effective of the two fatty acids [36]. However, a second study showed rats fed an EPA-enriched diet had an increased incidence of arthritis in a collagen-induced arthritis (CIA) model [37]. Olson et al. demonstrated that dietary supplementation with DHA, but not with fish oil or DHA/EPA, significantly reduced arthritis severity, anti-collagen antibody production and inflammation associated with CIA in mice [38]. A recent study by Torres-Guzman et al. has shown an antinociceptive and anti-inflammatory effect of DHA following repeated systemic or intra-articular treatment in a mouse model of chronic CFA-induced knee arthritis [39]. To our knowledge, the biochemical effects of ω3 DPA have not been extensively studied in preclinical models due to the limited availability and high cost of pure compound.

In the present study, we assessed the ability of MAG-EPA, MAG-DHA and MAG-DPA to resolve inflammation in an in vivo model of RA induced by CFA. Fatty acids in monoglyceride form confer increased bioavailability of ω3 and are generally recognized as safe and are widely used as emulsifying agent in the food industry. In a previous study, we have demonstrated that DHA monoacylglyceride increased the systemic bioavailability of DHA compared to commercially available marine oil [3032]. Omega-3 monoglycerides have better solubility in physiological solution and pharmacokinetics than omega-3 methyl ester or ethyl ester (EE) and more stable than omega-3 free fatty acid. Preclinical and clinical studies showed that the intestinal absorption of DHA and EPA given as EE was lower than seen in the case of triglyceride (TG) or free acid [40, 41]. Moreover, Dyerberg et al. and Cruz-Hernendez et al. have shown that EPA in the form of monoacylglyceride alone or in re-esterified TGs increases the oral bioavailability of EPA compared to natural TG form made from fish oil [40, 42]. Moreover, Banno et al. demonstrated that DHA monoglycerides and diglyceride are absorbed and transported more effectively than DHA-TG and EE in rats under a water-restricted condition [43]. In a preclinical model, Cruz-Hernandez et al. have shown that malabsorption due to enzyme insufficiency may lead to decreased circulating and tissue levels of EPA and such a deficiency can be reversed using MAG provided as sn-1(3)-MAG or protected sn-2-MAG [42]. Hence, Philippoussi et al. demonstrated that lipids in monoglyceride form display better induction of apoptosis in T-cells when compared with corresponding free fatty acid [44]. According to these data, we thought that the MAG-ω3 might be favorable in terms of absorption and utilization efficiency. Herein, our data revealed that MAG-EPA and MAG-DPA treatments were more effective than MAG-DHA in resolving inflammation and reducing arthritis severity in our preclinical model of RA. Histopathological analysis also correlated with the reduction in clinical scores, showing an overall reduction in both inflammation and bone and cartilage destruction in joints of animals treated with MAG-EPA or MAG-DPA.

Current literature indicates that supplemental ω3 PUFA decreases inflammatory cytokines [16] and eicosanoids [17, 38] in patients with RA. As a result, these effects should reduce pain and cartilage destruction which, in turn, may lead patients to decrease their use of pain-controlling drugs. Randomized controlled trials of ω3 fatty acids (at doses between 1 and 7g per day) in RA have reported improvements in several clinical outcomes including reduced duration of morning stiffness, reduced number of tender or swollen joints, reduced joint pain, reduced time to fatigue, increased grip strength and decreased use of pain-controlling drugs [3, 18, 45]. In a recent meta-analysis encompassing data from 17 trials on ω3 fatty acids and pain [26], fish oil was found to reduce patient-assessed joint pain, duration of morning stiffness, number of tender joints and use of pain-controlling drugs. It is therefore of key clinical interest to find an easy-to-use, well-absorbed ω3 PUFA that exerts a pro-resolving effect and consequently with the ability to reduce arthritis severity and progression.

Possible mechanisms underlying the anti-inflammatory effect of MAG-EPA and MAG-DPA in the current CFA model of arthritis

Although several studies have demonstrated anti-inflammatory effects of ω3 PUFA [3, 18], less is known as to the molecular mechanisms underlying these effects. One possible explanation, based on current literature, is that both direct and indirect effects may explain the biological actions of ω3 PUFA. Direct effects may include competition of DHA, EPA or DPA with arachidonic acid as a substrate for COX and LOX, thus reducing the production of inflammatory eicosanoids [3, 4648]. Moreover, we and others have recently demonstrated that the anti-inflammatory actions of ω3 PUFA and MAG-ω3 compounds may partially be explained by inhibition of NFκB-mediated COX-2 induction and activity [11, 49]. Expression of both COX-1 and COX-2 is increased in the synovium of patients with RA [11]; in addition, synovial fluid contains high levels of pro-inflammatory eicosanoid products from both the COX and LOX pathways [11] as well as high levels of pro-inflammatory cytokines including TNF, IL-1β, IL-17A, IL-6, IL-8 and GMCFS [50]. In this study, we demonstrate that MAG-EPA treatment is able to reduce the NFκB and p38 MAPK activation pathways, resulting in decreased levels of pro-inflammatory mediators such as COX-2, IL-17A, TNFα, IL-6, IL-1β, MMP-2 and MMP-9.

Indirect effects may also contribute to the biological actions of ω3 PUFA, including the participation of Rvs and protectins, which are lipid mediators enzymatically synthesized in vivo from EPA, DPA or DHA and shown to promote the resolution of inflammation with greater potency than their parent precursors [14, 51]. To date, there are only limited data investigating the actions of Rvs in animal models of arthritis. Accordingly, protective effects of aspirin-triggered-RvD1 (AT-RvD1) were observed following an intraplantar injection of CFA as a model of inflammatory arthritic pain [52]. In this latter study, AT-RvD1 (100 ng intraperitoneally twice daily) was shown to have antihyperalgesic effects, reducing hind paw withdrawal frequency, which was associated with decreased TNFα and IL-1β within the paw [52]. Moreover, several Rvs including RvD1, RvD2 and RvE1 have recently been identified as potent analgesics for treating inflammatory pain, acting as potent endogenous inhibitors that differentially regulate transient receptor potential subtype V1 (TRPV1) and A1 (TRPA1) agonist-elicited acute pain [14, 51].

RA is also known to be directly associated with an increase in ω-6 and a reduction in ω-3 fatty acid levels in blood circulation and tissues [3]. Previous studies from our group have shown that MAG-ω3 treatment increases the level of ω3 PUFA in plasma, red blood cells and tissues, suggesting a high ω3 PUFA bioavailability and thereby likely contributing to reducing inflammation [3032]. We also established that MAG-ω3 compounds were metabolized by lipoxygenases and CYP450 to generate metabolites mediating anti-inflammatory effects in our experimental models [3032]. We propose that MAG-EPA not only improves the plasma and cell/tissue content of EPA but also increases the production of beneficial metabolites such as Rvs [14] and exerts pro-resolving actions in our model of RA. Accordingly, elevated levels of 5-LO and 15-LO (key enzymes involved in Rv and lipoxin biosynthesis) have also been detected in RA synovium [53, 54]. A study using mass spectrometry-based lipidomic analyses has identified RvD5 and Maresin 1(MaR1) within the synovial fluid from RA patients [55]. Such findings warrant further study, such as stratifying patients according to disease severity, and taking into account differences in therapeutic and dietary intervention with ω3 supplementation.

Hypotheses would suggest that vitamin E and ω3 PUFAs have synergistic anti-inflammatory effects [56]. However, vitamin E is a potent antioxidant interrupting lipid peroxidation that has been purported to have antagonistic effects to ω3 PUFA, in particular in carcinogenesis [57]. Our results corroborate the hypothesis of a converse interaction between ω3 PUFA and vitamin E intake on inflammatory biomarkers. PUFAs are able to auto-oxidize such that their incorporation has been found to induce lipid peroxidation and apoptosis in vitro and in animal models of cancer [58, 59]. In these latter studies, ω3 PUFAs led to tumor growth suppression while adding vitamin E to ω3 PUFAs abolished this effect [58, 59], suggesting that ω3 PUFA-induced lipid peroxidation is likely not toxic per se but rather acts as a tumor cell growth and apoptosis regulator [60]. Moreover, in lung cells, antioxidants have been demonstrated to increase tumor cell proliferation in vitro and in vivo by reducing p53 activation [61]. Experimental studies and large clinical trials quite convincingly suggest that antioxidants, including isoflavones, carotenes and vitamins, should not be recommended for the prevention of lung cancer and that their use may promote tumor growth [6264]. Moreover, an epidemiological study by Julia et al. demonstrated an inverse relationship between PUFA intake and elevated levels of CRP in individuals taking vitamin E supplements [65]. Such interaction between PUFAs and vitamin E intake in inflammation will clearly necessitate further investigation in preclinical models of RA and human studies.

Conclusion

The present findings demonstrate that MAG-EPA, without vitamin E, exerts anti-inflammatory properties in a CFA animal model of arthritis. Furthermore, when administrated per os, MAG-EPA represents a stable compound which could serve as a precursor to generate a variety of PUFA-derived mediators such as Rvs known to directly mediate anti-inflammatory and pro-resolving effects through specific receptors. Consequently MAG-EPA formulations without vitamin E could provide a new and interesting approach for the management of rheumatoid arthritis diseases.

Abbreviations

AT-RvD1: 

aspirin-triggered-resolvin D1

BSA: 

bovine serum albumin

CFA: 

complete Freund’s adjuvant

CIA: 

collagen-induced arthritis

COX-2: 

cyclooxygenase-2

CRP: 

C-reactive protein

CYP450: 

cytochrome P450

EE: 

ethyl ester

ELISA: 

enzyme-linked immunosorbent assay

GI: 

gastrointestinal

GMCFS: 

granulocyte/macrophage colony stimulating factor

IL-17A: 

interleukin 17A

IL-1β: 

interleukin 1β

IL-6: 

interleukin 6

LOX: 

lipoxygenase

LTB4: 

leukotriene B4

MAG-DHA: 

docosahexaenoic acid monoglyceride

MAG-DPA: 

docosapentaenoic acid monoglyceride

MAG-EPA: 

eicosapentaenoic acid monoglyceride

MaR1: 

maresin 1

MMP: 

matrix metalloproteinase

NFκB: 

nuclear factor kappa B

NSAID: 

nonsteroidal anti-inflammatory drug

p38 MAPK: 

p38 mitogen-activated protein kinase

PD1: 

protectin D1

PGE2: 

prostaglandin E2

PUFA: 

polyunsaturated fatty acid

RA: 

rheumatoid arthritis

RvD1: 

resolvin D1

RvD2: 

resolvin D2

RvD5: 

resolvin D5

RvE1: 

resolvin E1

SEM: 

standard error of the mean

TBS: 

Tris-buffered saline

TG: 

triglyceride

TNFα: 

tumor necrosis factor α

Declarations

Acknowledgements

We wish to thank Mr Pierre Pothier for critical review of the manuscript. This work was supported by the Fonds d’amorçage de partenariat UQAR-Merinov.

Authors’ Affiliations

(1)
SCF Pharma
(2)
Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke
(3)
Department of Biology, Université du Québec à Rimouski

References

  1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903–11.View ArticlePubMedGoogle Scholar
  2. Bluml S, Redlich K, Smolen JS. Mechanisms of tissue damage in arthritis. Semin Immunopathol. 2014;36:531–40.View ArticlePubMedGoogle Scholar
  3. Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, et al. Inflammatory disease processes and interactions with nutrition. Br J Nutr. 2009;101:S1–S45.PubMedGoogle Scholar
  4. Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:545493.PubMed CentralPubMedGoogle Scholar
  5. Deleuran BW, Chu CQ, Field M, Brennan FM, Mitchell T, Feldmann M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum. 1992;35:1170–8.View ArticlePubMedGoogle Scholar
  6. Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 1993;52:870–5.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet. 1988;2:706–9.View ArticlePubMedGoogle Scholar
  8. Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, et al. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis. 1990;49:480–6.PubMedGoogle Scholar
  9. Westacott CI, Whicher JT, Barnes IC, Thompson D, Swan AJ, Dieppe PA. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis. 1990;49:676–81.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Kojima F, Naraba H, Sasaki Y, Okamoto R, Koshino T, Kawai S. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J Rheumatol. 2002;29:1836–42.PubMedGoogle Scholar
  11. Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992;89:97–108.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Lo V, Meadows SE, Saseen J. When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis? J Fam Pract. 2006;55:260–2.PubMedGoogle Scholar
  13. Calder PC, Zurier RB. Polyunsaturated fatty acids and rheumatoid arthritis. Curr Opin Clin Nutr Metab Care. 2001;4:115–21.View ArticlePubMedGoogle Scholar
  14. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011;111:5922–43.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Wann AK, Mistry J, Blain EJ, Michael-Titus AT, Knight MM. Eicosapentaenoic acid and docosahexaenoic acid reduce interleukin-1beta-mediated cartilage degradation. Arthritis Res Ther. 2010;12:R207.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, Bartholomew LE, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum. 1990;33:810–20.View ArticlePubMedGoogle Scholar
  17. Cleland LG, French JK, Betts WH, Murphy GA, Elliott MJ. Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol. 1988;15:1471–5.PubMedGoogle Scholar
  18. Cleland LG, James MJ. Marine oils for antiinflammatory effect – time to take stock. J Rheumatol. 2006;33:207–9.PubMedGoogle Scholar
  19. Berbert AA, Kondo CR, Almendra CL, Matsuo T, Dichi I. Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. Nutrition. 2005;21:131–6.View ArticlePubMedGoogle Scholar
  20. Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology (Oxford). 2008;47:665–9.View ArticleGoogle Scholar
  21. Kjeldsen-Kragh J, Lund JA, Riise T, Finnanger B, Haaland K, Finstad R, et al. Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis. J Rheumatol. 1992;19:1531–6.PubMedGoogle Scholar
  22. Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaouette J, et al. Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann Intern Med. 1987;106:497–503.View ArticlePubMedGoogle Scholar
  23. Nielsen GL, Faarvang KL, Thomsen BS, Teglbjaerg KL, Jensen LT, Hansen TM, et al. The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a randomized, double blind trial. Eur J Clin Invest. 1992;22:687–91.View ArticlePubMedGoogle Scholar
  24. Skoldstam L, Borjesson O, Kjallman A, Seiving B, Akesson B. Effect of six months of fish oil supplementation in stable rheumatoid arthritis. A double-blind, controlled study. Scand J Rheumatol. 1992;21:178–85.View ArticlePubMedGoogle Scholar
  25. Volker D, Fitzgerald P, Major G, Garg M. Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol. 2000;27:2343–6.PubMedGoogle Scholar
  26. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007;129:210–23.View ArticlePubMedGoogle Scholar
  27. Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis. 2015;74:89–95.View ArticlePubMedGoogle Scholar
  28. Fortin S. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof, US819690, 2012, US8222295, 2012.Google Scholar
  29. Fortin S. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof, CA2672513, 2008, CA2677670, 2010, US8119690, 2011.Google Scholar
  30. Morin C, Hiram R, Rousseau E, Blier PU, Fortin S. Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2014;307:H574–86.View ArticlePubMedGoogle Scholar
  31. Morin C, Fortin S, Cantin AM, Sirois M, Sirois C, Rizcallah E, et al. Anti-cancer effects of a new docosahexaenoic acid monoacylglyceride in lung adenocarcinoma. Recent Pat Anticancer Drug Discov. 2013;8:319–34.View ArticlePubMedGoogle Scholar
  32. Morin C, Fortin S, Cantin AM, Rousseau E. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. Am J Respir Cell Mol Biol. 2011;45:366–75.View ArticlePubMedGoogle Scholar
  33. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–61.View ArticlePubMedGoogle Scholar
  34. Park Y, Lee A, Shim SC, Lee JH, Choe JY, Ahn H, et al. Effect of n-3 polyunsaturated fatty acid supplementation in patients with rheumatoid arthritis: a 16-week randomized, double-blind, placebo-controlled, parallel-design multicenter study in Korea. J Nutr Biochem. 2013;24:1367–72.View ArticlePubMedGoogle Scholar
  35. Russell FD, Burgin-Maunder CS. Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar Drugs. 2012;10:2535–59.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Volker DH, FitzGerald PE, Garg ML. The eicosapentaenoic to docosahexaenoic acid ratio of diets affects the pathogenesis of arthritis in Lew/SSN rats. J Nutr. 2000;130:559–65.PubMedGoogle Scholar
  37. Prickett JD, Trentham DE, Robinson DR. Dietary fish oil augments the induction of arthritis in rats immunized with type II collagen. J Immunol. 1984;132:725–9.PubMedGoogle Scholar
  38. Olson MV, Liu YC, Dangi B, Paul Zimmer J, Salem Jr N, Nauroth JM. Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis. Inflamm Res. 2013;62:1003–13.View ArticlePubMedGoogle Scholar
  39. Torres-Guzman AM, Morado-Urbina CE, Alvarado-Vazquez PA, Acosta-Gonzalez RI, Chávez-Piña AE, Montiel-Ruiz RM, et al. Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of Complete Freund's Adjuvant-induced knee arthritis. Arthritis Res Ther. 2014;16:R64.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Dyerberg J, Madsen P, Møller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010;83:137–41.View ArticlePubMedGoogle Scholar
  41. Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun. 1988;156:960–3.View ArticlePubMedGoogle Scholar
  42. Cruz-Hernandez C, Thakkar SK, Moulin J, Oliveira M, Masserey-Elmelegy I, Dionisi F, et al. Benefits of structured and free monoacylglycerols to deliver eicosapentaenoic (EPA) in a model of lipid malabsorption. Nutrients. 2012;4:1781–93.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Banno F, Doisaki S, Shimizu N, Fujimoto K. Lymphatic absorption of docosahexaenoic acid given as monoglyceride, diglyceride, triglyceride, and ethyl ester in rats. J Nutr Sci Vitaminol. 2002;48:30–5.View ArticlePubMedGoogle Scholar
  44. Philippoussis F, Przybytkowski E, Fortin M, Arguin C, Pande SV, Steff AM, et al. Derivatives of monoglycerides as apoptotic agents in T-cells. Cell Death Differ. 2001;8:1103–12.View ArticlePubMedGoogle Scholar
  45. Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br J Nutr. 2012;107:S171–84.View ArticlePubMedGoogle Scholar
  46. van der Tempel H, Tulleken JE, Limburg PC, Muskiet FA, van Rijswijk MH. Effects of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis. 1990;49:76–80.PubMed CentralView ArticlePubMedGoogle Scholar
  47. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167:4710–8.View ArticlePubMedGoogle Scholar
  48. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum. 2007;56:2111–5.View ArticlePubMedGoogle Scholar
  49. Nauroth JM, Liu YC, Van Elswyk M, Bell R, Hall EB, Chung G, et al. Docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo. Lipids. 2010;45:375–84.View ArticlePubMedGoogle Scholar
  50. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 1999;38:3–7.PubMedGoogle Scholar
  51. Park CK, Xu ZZ, Liu T, Lu N, Serhan CN, Ji RR. Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J Neurosci. 2011;31:18433–8.PubMed CentralView ArticlePubMedGoogle Scholar
  52. Lima-Garcia JF, Dutra RC, da Silva K, Motta EM, Campos MM, Calixto JB. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br J Pharmacol. 2011;164:278–93.PubMed CentralView ArticlePubMedGoogle Scholar
  53. Gheorghe KR, Korotkova M, Catrina AI, Backman L, af Klint E, Claesson HE, et al. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther. 2009;11:R83.PubMed CentralView ArticlePubMedGoogle Scholar
  54. Hashimoto A, Hayashi I, Murakami Y, Sato Y, Kitasato H, Matsushita R, et al. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. J Rheumatol. 2007;34:2144–53.PubMedGoogle Scholar
  55. Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta. 2012;1821:1415–24.PubMed CentralView ArticlePubMedGoogle Scholar
  56. Stoll BA. Breast cancer and the western diet: role of fatty acids and antioxidant vitamins. Eur J Cancer. 1998;34:1852–6.View ArticlePubMedGoogle Scholar
  57. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997;82:291–5.View ArticlePubMedGoogle Scholar
  58. Chajes V, Sattler W, Stranzl A, Kostner GM. Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and vitamin-E. Breast Cancer Res Treat. 1995;34:199–212.View ArticlePubMedGoogle Scholar
  59. Gonzalez MJ, Schemmel RA, Dugan Jr L, Gray JI, Welsch CW. Dietary fish oil inhibits human breast carcinoma growth: a function of increased lipid peroxidation. Lipids. 1993;28:827–32.View ArticlePubMedGoogle Scholar
  60. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. 2004;79:935–45.PubMedGoogle Scholar
  61. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 2014;6(221):221ra15.Google Scholar
  62. Allred CD, Ju YH, Allred KF, Chang J, Helferich WG. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis. 2001;22:1667–73.View ArticlePubMedGoogle Scholar
  63. Robinson C, Woo S, Walsh A, Nowak AK, Lake RA. The antioxidants vitamins A and E and selenium do not reduce the incidence of asbestos-induced disease in a mouse model of mesothelioma. Nutr Cancer. 2012;64:315–22.View ArticlePubMedGoogle Scholar
  64. Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 2013;3:120144.PubMed CentralView ArticlePubMedGoogle Scholar
  65. Julia C, Touvier M, Meunier N, Papet I, Galan P, Hercberg S, et al. Intakes of PUFAs were inversely associated with plasma C-reactive protein 12 years later in a middle-aged population with vitamin E intake as an effect modifier. J Nutr. 2013;143:1760–6.View ArticlePubMedGoogle Scholar

Copyright

© Morin et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement